For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...

A stark divergence is emerging at telehealth provider Hims & Hers. The company is aggressively pursuing operational expansion, yet this stands in sharp c ...

Hims & Hers HIMS recently announced that it is expanding access to its comprehensive Weight Loss Program to customers in the ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Hims reports that 70% of Americans believe an economic downturn encourages healthier habits, like cooking at home and ...

Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $373,316, and 7 were calls, valued ...

Against this backdrop, short sellers continued to concentrate on consumer names worldwide--particularly across EMEA--while Software & Services also drew significant U.S. short-selling activity, ...

No financial data available at this time. Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

Hims & Hers ( HIMS) is bringing access to its comprehensive weight loss program to the UK.